@DrSamuelBHume: One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results I feel inspired and…
Summary
A standing ovation greeted the full results of Daraxonrasib, a targeted therapy for pancreatic cancer, marking a major breakthrough. The researcher expresses inspiration that nothing is undruggable anymore.
View Cached Full Text
Cached at: 06/01/26, 05:32 PM
One of the most amazing things I’ve ever seen: a standing ovation for the full Daraxonrasib results
I feel inspired and energised, to put it mildly — we have a targeted therapy for pancreatic cancer now, and nothing is undruggable anymore https://t.co/D0qDtnMJb7
Similar Articles
Daily pill can double survival time for deadliest cancer, trial shows
A clinical trial found that the daily pill daraxonrasib doubles survival time for patients with pancreatic cancer, offering a significant breakthrough in treatment with fewer side effects compared to chemotherapy.
@EricTopol: Big progress vs cancer, folks. The kind of event curves from randomized trials that we've not seen before for a couple …
Big progress against two of the most deadly cancers reported from randomized trials, as highlighted by Eric Topol during the ASCO conference.
@EricTopol: The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the mo…
Eric Topol highlights the remarkable progress in cancer immunotherapy, with vaccines achieving cures or remissions in refractory cancers like pancreatic, melanoma, glioblastoma, renal, and triple-negative breast cancer, and directs readers to his Ground Truths newsletter for more.
ChatGPT and Cancer: How a Tech Founder Rewrote His Treatment Plan
GitLab co-founder Sid Sijbrandij open-sourced 25 TB of multi-omic tumor data and used ChatGPT-driven agents to design custom therapies, including a FAP-targeted radioligand and an mRNA vaccine, for his relapsed osteosarcoma.
Uncovering repurposed medicines to fight liver fibrosis
DeepMind's Co-Scientist AI helped identify two repurposed medicines that block liver fibrosis in lab tests, including a cancer drug that blocked 91% of a damage response, outperforming human expert selections.